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Breast cancer remains the most common cancer 
among women worldwide, with more than 1 million new 
case and 370,000 deaths each year [1]. Most breast 
cancer deaths are due to metastatic disease, not pri-
mary tumor burden [2, 3]. Surgery is still the main cura-
tive therapeutic modality for breast cancer. Although 
surgery often results in the successful removal of the 
primary tumor, the process of it could increase the risk of 
metastases of residual cancer cells to other organs [4]. 
The effect of surgery on metastasis may be attributed 
to a number of factors, including immunosuppression 
after surgical stress, action of cytokines or changes of 
tumor microenvironment [5]. However, the underlying 
mechanisms are still not fully elucidated. Understanding 
of the connection between breast cancer metastasis and 
surgical wound will lead to the establishment of a proper 
treatment strategy for postoperative cancer patient. 
Matrix metalloproteinase 9 (MMP-9) is one of the 
family members that are capable to degrade almost of 
extracellular matrix proteins, and is closely related to tu-
mor invasion and metastasis [6]. Recent study has shown 
that MMP-9 not only degrades matrix proteins, but also 
«nonmatrix», such as growth factors, cytokines, chemo-
kines or death receptors [7–9], suggesting that MMP-9 
may regulate both tumor microenvironment [10–12] and 
metastasis [13, 14]. Tumor and stromal cells can mutually 
induce MMPs, which in turn contribute to overall tumor 
invasion [15]. Clinical data has revealed that serum MMPs 
are related to prognosis of cancer patients [13]. Thus, 
objective evaluation of the correlation between MMP-9 
expression level and surgical stress may provide useful 
marker to monitor metastasis after surgery.
Angiogenesis plays a key role in both wound he a-
ling and ability of cancer cells to survive and growth. 
Investigation into angiogenesis response to surgical 
stress may help guide surgical approaches and timing 
of antiangiogenic therapy. Vascular endothelial growth 
factor (VEGF) is one of important mediators of angio-
genesis and is known to be a critical factor to stimulate 
tumor growth and metastasis [16–19]. Establishment 
of the correlation of VEGF expression level in serum or 
tumor cells with postoperation metastasis may provide 
valuable information for predicting metastasis.
To further evaluate the relations of surgery, tumor 
metastasis and their mechanisms, we established 
MDA-MB-435 human breast caner xenograft model. 
Expression levels of MMP-9 and VEGF in host serum 
and tumors were tested at different time points with 
ELISA and zymography and correlated to tumor growth 
and postoperative metastasis. 
MATERIALS AND METHODS
Cell lines. Originally the human breast carcinoma 
cell line MDA-MB-435 was obtained from the Ameri-
can Type Culture Collection and maintained at 37 °C 
in an atmosphere of 5% CO2 in humidified air. Cells 
were cultured in L-15 (Invitrogen) supplemented with 
penicillin/streptomycin (100 IU/ml and 100 µg/ml) and 
10% fetal bovine serum (FBS).
Mice. BALB/ca female nude mice at the age of 
5 weeks (Shanghai Institute of Materia Medica, Chi-
nese Academy of Science, Shanghai, China) were 
used in this study. Mice were kept in laminar-flow cabi-
nets under specific pathogen-free conditions, cared, 
and handled according to the recommendations of the 
NIH Guidelines for Care and Use of Laboratory Ani-
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mals. Experimental protocol was provided by Shanghai 
Medical Experimental Animal Care Committee.
Tumor model and surgical procedures. When mice 
were at 6 weeks of age, tumor cells (6 × 106/mouse) were 
injected into the right thoracic mammary fat pad of all 
mice to produce orthotopic primary tumors. Mice were 
randomly assigned to the control group (n = 14), surgery 
group (n = 17) and sham surgery group (n = 11). Tumor re-
section (surgery group) involved making an elliptic incision 
around the tumor and dissecting it away from the chest 
wall. The tumor mass was gently removed and the incision 
closed with wound clips. Sham treatment (sham surgery 
group) involved making a 2-cm incision lateral to the pri-
mary tumor, leaving the primary tumor intact and closed 
the incision with wound clips. All surgical procedures were 
done under general anesthesia pentobarbital (0.34 mg of 
body mass) administered by i.p. injection.
Blood serum isolation. Blood was collected pe-
riodically by cutting off vena caudalis after surgery. 
After 8 min centrifugation at 2800 g, blood serum was 
extracted and frozen at -80 oC.
Tumor protein extraction. Tumor tissue was 
homogenized in lysis buffer containing 150 mM 
NaCl, 100 mM Tris, 1% Tween-20, 50 mM diethyl di-
thiocarbamate, 1 mM phenylmethylsulfonyl fluoride, 
0.001 µM aprotinin, and 1 µM pepstatin. The mixture 
was stirred for 1 h at 4 °C and then centrifuged at 
2800 g for 20 min at 4 °C. The supernatant was sepa-
rated and determined by protein assay. Equal amounts 
of protein were applied to 12% SDS-polyacrylamide 
gel and separated by electrophoresis.
Gelatin zymography.  Zymography was carried 
out by electrophoresis in the presence of SDS in 10% 
discontinuous polyacrylamide gels containing 0.1% 
gelatin. Samples were loaded on the gel after dilution 
into sample buffer (2 ×) consisting of 60 mM Tris-HCl, pH 
6.8, 25% glycerol, 2% SDS and 0.1% bromophenol blue. 
Electrophoresis was performed under non-reducing 
conditions at 20 mA for 3 h at room temperature. The gel 
was washed twice for 30 min each in 2.5% Triton X-100 to 
remove SDS, incubated in substrate buffer (50 mM Tris-
HCl, 5 mM CaCl2, 0.2 mM NaCl, 0.02% Brij-35, pH 7.5) 
for 24 h at 37 °C. Gel was stained with 2% Coomassie 
brilliant blue G-250 (Pierce Rockford, IL) for 30 min at 
room temperature, and destained (10% ethanol, 10% 
acetic acid, 80% water). Zymograms were analyzed by 
densitometry and the quotient between the intensities 
obtained for pro-MMP-9 calculated, and data were pre-
sented as fold change compared to control [20].
ELISA. Mouse Pro-MMP-9, Mouse VEGF levels in 
serum and tumor extracts (50–200 g) were measured by 
enzyme immunoassay (R&D Systems) [21]. The serum 
samples were diluted to appropriate concentrations, and 
analyzed in duplicate. Absorbances were determined at 
450 nm. Readings at 570 nm were subtracted from the 
readings at 450 nm to correct for optical imperfections. 
At the same time, a standard curve was obtained by linear 
regression analysis of protein concentration versus absor-
bance in a double logarithmic plot, basing on the standard 
curve to generate for each set of samples assayed.
Histologic and immunohistochemical analysis of 
metastases. At the end points, mice were necropsied 
and organs (including lung, brain, liver, kidney, heart, 
and spleen) were examined for surface metastases by 
microscopy (× 8). The whole lungs and livers from each 
mouse were fixed in 10% neutral-buffered formalin, em-
bedded in paraffin, and were sectioned at every 100 µm 
for 10 pieces [22]. Tissue sections were stained with H&E 
and examined by light microscopy for metastases.
The percent metastatic burden in the lungs was 
quantified by point counting method. 10 pieces of 
H&E-stained slide per mouse were examined using light 
microscopy (× 100) for metastases. The biggest number 
of metastases in the 10 pieces of H&E-stained slide was 
calculated as the metastatic burden of each mouse.
Statistical analysis. The data were expressed as 
the mean ± SD. Differences between means were de-
termined using the Student’s test when groups passed 
both a normality test and an equal variance test. χ2 test 
was used for the incidence rate of lung metastasis. 
Software stata 7.0 was used for correlations analysis. 
Significance was accepted at P < 0.05.
RESULTS
Surgical wound promoted pulmonary metas-
tasis of human breast cells. To determine whether 
surgical wound would stimulate metastasis of tumor 
cells, all mice were necropsied at the endpoint of experi-
ments and organs (including lung, brains, liver, kidney, 
heart, and spleen) were examined for metastases with 
microscope. Superficial metastases were not observed 
in organs examined except for lung. Incidence of sur-
face lung metastases occurrence was 9 of 14 (64%) in 
the control group and 11 of 11 (100%) in the sham group 
(P < 0.05, table 1). No surface lung metastases were 
observed in surgery group.
Table 1. Effects of surgical wound on the incidence of spontaneous 
 metastases from MDA-MB-435 primary mammary tumor in nude mice
Group Pulmonary metastasisSuperficial evidence Histologic evidence 
Control 9/14 14/14
Surgery 1/17 1/17
Sham surgery 11/11* 11/11
*Statistically significant (P < 0.05), compared with control.
Histologic sections of lung organ were further 
examined by H&E staining to compare the metastatic 
burdens between control and sham groups. We found 
the number of metastasis foci per mouse (17.0 ± 10.8) 
was significantly higher in the sham group (8.8 ± 6.2) 
than that in the control group (P < 0.05, Fig. 1). These 
data suggested surgical wound could promote pulmo-
nary metastasis of human breast cells. 
Surgical wound could enhance the interaction 
of cancer and host cells to produce Pro-MMP-9. To 
evaluate the correlation between MMP-9 level in serum 
and surgical stress, we measured the postoperative levels 
of serum MMP-9 at the different time points by zymogra-
phy. The host and human MMP-9 can be distinguished, 
as their molecular weights are apparently different [23]. As 
shown on Fig. 2, a, b, c, during days 1 to 3 after surgery, 
levels of host Pro-MMP-9 were significantly higher in the 
surgery and sham groups as compared with the control 
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group (P < 0.0001), but no significant difference was 
observed between the surgery and sham groups. In the 
following two weeks three groups of mice showed levels of 
Pro-MMP-9 with mild difference. However, from day 19 the 
levels of host Pro-MMP-9 in the sham group became sig-
nificantly higher than that in other two groups (P < 0.05). 
The high levels in sham group were maintained to day 40. 
Notably, no activated MMP-9 was detected during whole 
process. In addition, the level of host Pro-MMP-9 in serum 
measured by ELISA at the day of 60 was similar to the level 
measured by zymography (data not shown), conforming 
the data were reliable. These observations not only indi-
cated that surgical wound promoted expression of host 
Pro-MMP-9, but also implied that surgical wound resulted 
in interaction of cancer cells with host cells to produce 
Pro-MMP-9 during certain period after operation. 
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Fig. 1. Effects of surgical wound on the metastatic burden in lungs 
of nude mice with MDA-MB-435 primary tumor. a: Metastases on 
lung surface observed by microscopy (× 8). b: H&E-stained thin 
sections of lungs examined for the presence of metastases (× 100). 
c: The average metastatic burden in the lungs quantified using point 
counting method, (*) for statistically significant when P < 0.05.
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Fig. 2. Effects of surgical wound on the level of mouse 
Pro-MMP-9 in serum examined by zymography. a: The mouse Pro-
MMP-9, instead of human pro-MMP-9, identified. Recombinant 
mouse Pro-MMP-9 standard was used as a marker.  Abbreviations: 
M serum — mouse serum; H serum — human serum; Tumor — 
MDA-MB-435 primary tumor. b: The activity of mouse Pro-MMP9 
at three time points. c: Quantitative analysis of Pro-MMP-9 activity 
determined by densitometry of respective bands (control group 
taken as 100%). The results shown in the histogram were the 
mean ± standard deviation. As compared with control, (*) P < 0.05, 
as compared with control and surgery, (**) P < 0.05. 
Level of host Pro-MMP-9 correlated with tumor 
volume and the metastatic burden. To evaluate the 
effect of host Pro-MMP-9 on growth and metastasis 
of breast cancer cells we examined tumor volume and 
metastatic burden in our animal model. As shown in 
Fig. 3, tumor volume in sham surgery group was larger 
during weeks 4 to 6, which corresponded to the postop-
erative period when higher serum Pro-MMP-9 level was 
observed. Statistic analysis indicated a positive correla-
tion of host serum Pro-MMP-9 level and tumor volume 
(P < 0.05, Table 2). Furthermore, the level of host serum 
Pro-MMP-9 is positively correlated to metastatic burden 
(r = 0.52, P = 0.0256) at the endpoint of experiments.
Table 2. Correlation between mouse Pro-MMP-9 level and tumor volume 
in sham surgical group. 
Time (d) 19 26 33 40
Corr (r) 0.53 0.41 0.48 0.55
P value 0.011 0.042 0.014 0.015
Surgical wound promoted mouse VEGF expres-
sion in tumor. To investigate the effect of surgical 
wound on the host VEGF expression, we measured 
the level of mouse VEGF in tumor by ELISA. Compared 
with control group, VEGF level of tumor tissues was 
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significantly higher in sham surgery group (P < 0.05, 
Fig. 4, a). The expression level of VEGF in blood serum 
was also measured. Interestingly, the level of serum 
VEGF was significantly lower in sham surgery group 
than in control group (P < 0.05, Fig. 4, b). These data 
suggested that surgical wound could mainly promote 
host VEGF expression in tumor tissues.
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Fig. 3.  Effects of surgical wound on the growth of MDA-MB-435 
mammary primary tumors in nude mice. Tumor size was tested 
and tumor volume was calculated weekly. The results represent the 
mean ± standard deviation. (*) statistically significant, P < 0.05.
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Fig. 4.  Effects of surgical wound on mouse VEGF expression. 
a: ELISA validation of VEGF expression in tumor. b: ELISA vali-
dation of VEGF expression in serum. The results shown in the 
histogram were the mean ± standard deviation. (*) statistically 
significant (P < 0.05) compared to control.
DISCUSSION
Our present study demonstrated surgical wound 
had a promoting effect on tumor growth and pulmo-
nary metastasis of human breast cells, if tumor cells 
remain in bodies. This effect might be related to the 
postoperative interaction of cancer and host cells that 
resulted in production of host Pro-MMP-9. Surgical 
process could also increase the VEGF expression in 
tumor tissues. This implicated surgical wound-pro-
duced host Pro-MMP-9 and tumor cell VEGF might be 
important mediators leading to metastasis of residual 
breast cancer after surgery.
Recent studies have shown that the reactive stroma 
adjacent to carcinoma cells in wound repair is fundamen-
tally different from the stroma of normal adult tissues in 
many human cancers [24]. Breast stroma accounts for 
more than 80% of the resting breast volume [25]. Inter-
actions between cancer cells and surrounding stroma 
fibroblasts have been suggested to play a critical role in 
tumor invasion and metastasis [26–28]. Experimental 
in vitro and in vivo findings have indicated that interaction 
of tumor and stroma cells can mutually induce MMPs, 
which in turn can contribute to overall tumor invasion 
and metastasis [29–31]. The increased host serum Pro-
MMP-9 and VEGF expression in tumor cells induced by 
operative wound might be resulted from the interaction of 
cancer cells and surrounding stromal cells. The highest 
level of host serum Pro-MMP-9 was observed between 
three to six weeks after operation. The increase level 
was positively related to enhanced tumor growth and 
metastasis, suggesting the level of serum Pro-MMP-9 
in this time period would provide useful information for 
monitoring postoperative metastasis of breast cancer. 
Additionally, VEGF level in tumor tissues was informative 
with regard to the postoperative metastasis. Therefore, 
it  deserves determining whether combination of serum 
Pro-MMP-9 and VEGF level in tumor tissues are sensitive 
markers to monitor tumor metastasis after operation in 
future. Our work implies that it is necessary to formulate 
more suitable treatment prescriptions to reduce the risk 
of tumor metastasis.
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ХИРУРГИЧЕСКОЕ ВМЕШАТЕЛЬСТВО СТИМУЛИРУЕТ РОСТ 
ОПУХОЛИ И МЕТАСТАЗИРОВАНИЕ ЗА СЧЕТ АКТИВАЦИИ 
ЭКСПРЕССИИ MMP-9 И VEGF В МОДЕЛИ ОПУХОЛИ 
МОЛОЧНОЙ ЖЕЛЕЗЫ
Хирургическое лечение до сих пор остается главным терапевтическим подходом при лечении больных раком молочной 
железы. Хотя хирургическое удаление опухоли в большинстве случаев достаточно эффективно, в то же время оно может 
увеличить риск метастазирования остаточных опухолевых клеток. Понимание связи между метастазированием при раке 
молочной железы и операционной раной позволит выбрать наилучшую стратегию постоперационного лечения. Цель: 
определить влияние хирургического вмешательства на метастазирование опухоли. Методы: была создана модель рака 
молочной железы человека в виде ксенотрансплантата MDA-MB-435. Уровень Pro-матричной металлопротеиназы 9 
(Pro-MMP-9) и фактора роста эндотелия сосудов (VEGF) в сыворотке реципиента и опухолях оценивались в разные 
временные промежутки методом ELISA и зимографии. При этом определяли наличие корелляции между этими показа-
телями, ростом опухоли и постоперационными метастазами. Результаты: было показано, что операционная рана спо-
собствует росту опухоли молочной железы и ее метастазированию в легкие в случае, когда при удалении опухоли в ране 
остаются опухолевые клетки. Это может быть связано с постоперационным взаимодействием опухолевых и окружающих 
их нормальных клеток, которое приводит к экспрессии Pro-MMP-9. Удаление опухоли может также способствовать 
увеличению экспрессии VEGF опухолевыми клетками. Выводы: Pro-MMP-9, экспрессируемый нормальными клетками, 
окружающими постоперационную рану, а также VEGF, продуцируемый опухолевыми клетками, могут быть важными 
медиаторами метастазирования остаточных опухолевых клеток после хирургического вмешательства. 
Ключевые слова: операционная рана, метастазы, матричная металлопротеиназа 9, рак молочной железы, фактор роста 
эндотелия сосудов.
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